Nina Kreuzberger

Mrs. Nina Kreuzberger

Department 1 of internal medicine, University Hospital Cologne, Cologne, North Rhine-Westphalia, Germany
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2021 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
NKNina Kreuzberger
Nina Kreuzberger
CHCaroline Hirsch
Caroline Hirsch
KCKhai Li Chai
Khai Li Chai
ETEve Tomlinson
Eve Tomlinson
ZKZahra Khosravi
Zahra Khosravi
NSNicole Skoetz
Nicole Skoetz

16 November 2021 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
VPVanessa Piechotta
Vanessa Piechotta
AAAnne Adams
Anne Adams
MHMadhuri Haque
Madhuri Haque
BSBenjamin Scheckel
Benjamin Scheckel
NKNina Kreuzberger
Nina Kreuzberger
NSNicole Skoetz
Nicole Skoetz

16 August 2022 in Annals of Internal Medicine
Verified
Journal Article
Open access
LELise J. Estcourt
Lise J. Estcourt
CCClaudia S. Cohn
Claudia S. Cohn
MPMonica B. Pagano
Monica B. Pagano
CIClaire Iannizzi
Claire Iannizzi
NKNina Kreuzberger
Nina Kreuzberger
ATAaron A.R. Tobian
Aaron A.R. Tobian
The Association for the Advancement of Blood and Biotherapies developed clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma. This article describes the evidence and... Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a potential treatment of COVID-19. However, meta-analysis data and recommendations are limited. The Association for th...

31 May 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
VPVanessa Piechotta
Vanessa Piechotta
SMSibylle Mellinghoff
Sibylle Mellinghoff
CHCaroline Hirsch
Caroline Hirsch
ABAlice Brinkmann
Alice Brinkmann
CIClaire Iannizzi
Claire Iannizzi
NSNicole Skoetz
Nicole Skoetz
The efficacy of SARS-CoV-2 vaccination in patients with hematological malignancies (HM) appears limited due to disease and treatment-associated immune impairment. We conducted a systematic review of prospective studies published from 10/12/2021 onwards in medical databases to assess clinical efficacy parameters, humoral and cellular immunogenicity and adverse events (AE) following two doses of COVID-19 approved vaccines. In 57 eligible studies reporting 7393 patients, clinical outcomes were rarely reported and rates of SARS-CoV-2 infection (range 0–11.9%), symptomatic disease (0–2.7%), hospital admission (0–2.8%), or death (0–0.5%) were low. Seroconversion rates ranged from 38.1–99.1% across studies with the highest response rate in myeloproliferative diseases and the lowest in patients with chronic lymphocytic leukemia. Patients with B-cell depleting treatment had lower seroconversion rates as compared to other targeted treatments or chemotherapy. The vaccine-induced T-cell response was rarely and heterogeneously reported (26.5–85.9%). Similarly, AEs were rarely reported (0–50.9% ≥1 AE, 0–7.5% ≥1 serious AE). In conclusion, HM patients present impaired humoral and cellular immune response to COVID-19 vaccination with disease and treatment specific response patterns. In light of the ongoing pandemic with the easing of mitigation strategies, new approaches to avert severe infection are urgently needed for this vulnerable patient population that responds poorly to current COVID-19 vaccine regimens.

31 July 2020 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
NKNina Kreuzberger
Nina Kreuzberger
JDJohanna Aag Damen
Johanna Aag Damen
MTMarialena Trivella
Marialena Trivella
LELise J Estcourt
Lise J Estcourt
AAAngela Aldin
Angela Aldin
NSNicole Skoetz
Nicole Skoetz

3 April 2024 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
FFFarid Foroutan
Farid Foroutan
MMMartin Mayer
Martin Mayer
Gordon GuyattGordon Guyatt
Gordon Guyatt
RRRichard D. Riley
Richard D. Riley
RMReem A. Mustafa
Reem A. Mustafa
AIAlfonso Iorio
Alfonso Iorio
Prognostic models incorporate multiple prognostic factors to estimate the likelihood of future events for individual patients based on their prognostic factor values. Evaluating these models crucially involves conducting studies to assess their predictive performance, like discrimination. Systematic reviews and meta-analyses of these validation studies play an essential role in selecting models for clinical practice. In this paper, we outline 3 thresholds to determine the target for certainty rating in the discrimination of prognostic models, as observed across a body of validation studies. We propose 3 thresholds when rating the certainty of evidence about a prognostic model's discrimination. The first threshold amounts to rating certainty in the model's ability to classify better than random chance. The other 2 approaches involve setting thresholds informed by other mechanisms for classification: clinician intuition or an alternative prognostic model developed for the same disease area and outcome. The choice of threshold will vary based on the context. Instead of relying on arbitrary discrimination cut-offs, our approach positions the observed discrimination within an informed spectrum, potentially aiding decisions about a prognostic model's practical utility.